Reuters logo
BRIEF-Corbus Pharma outlines U.S. approval path for anabasum
2017年4月5日 / 下午12点44分 / 8 个月前

BRIEF-Corbus Pharma outlines U.S. approval path for anabasum

April 5 (Reuters) - Corbus Pharmaceuticals Holdings Inc :

* Corbus Pharmaceuticals to commence single Phase 3 study of anabasum for treatment of systemic sclerosis after guidance from end-of-phase 2 meeting with FDA

* Expects to enroll its first patient in single phase 3 study in fourth quarter of 2017

* Engaging EMA for discussing clinical development of anabasum to support application for marketing approval to treat systemic sclerosis

* Plans to complete enrollment of 52-week Phase 3 international study in 2018 with results expected in 2019, NDA application thereafter Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below